• Wondering if Hims & Hers Health at around US$30.56 is offering real value or just riding a wave of enthusiasm? This article breaks down what the current price may be implying about the business.
• The stock has posted returns of 6.0% over the last week and 46.6% over the past month, set against a negative 8.5% return year to date and a 163.7% return over three years.
• Recent news coverage has focused on Hims & Hers Health as a fast growing telehealth brand, with attention on its direct to consumer model and expanding product range in areas like hair loss and mental health. Commentary has also highlighted how the company sits within the broader digital health space, which can influence how investors think about its growth profile and risk.
• Even so, Hims & Hers Health currently scores 2 out of 6 on Simply Wall St's valuation checks. The next sections will compare several valuation approaches, then finish with a way to judge value that brings all these methods together.

Hims & Hers Health scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Hims & Hers Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes projected future cash flows and discounts them back to today, aiming to translate those future dollars into a single present value per share.

For Hims & Hers Health, the model uses last twelve months Free Cash Flow of about $139.1 million as a starting point, then layers on analyst estimates through 2030 and extrapolated figures beyond that. By 2030, projected Free Cash Flow is $442.5 million, with ten year projections stepping up each year from $121.8 million in 2026 to $745.1 million in 2035, all in $ and then discounted back using the 2 Stage Free Cash Flow to Equity model.

Pulling those projections together, Simply Wall St arrives at an estimated intrinsic value of $61.15 per share, compared with the current share price of around $30.56. That implies the stock is trading at roughly a 50.0% discount to this DCF estimate, which points to a sizable valuation gap based on these cash flow assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Hims & Hers Health is undervalued by 50.0%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks.

Approach 2: Hims & Hers Health Price vs Earnings

For profitable companies, the P/E ratio is a common way to see how much you are paying for each dollar of earnings. It links directly to what the business is currently earning, which many investors find easier to relate to than cash flow models.

Growth expectations and risk usually drive what looks like a “normal” P/E. Higher expected earnings growth or perceived resilience can support a higher P/E, while more uncertainty or thinner margins often mean a lower one is seen as reasonable.

Hims & Hers Health currently trades on a P/E of 54.27x, compared with a Healthcare industry average of about 24.32x and a peer average of 37.47x. Simply Wall St’s Fair Ratio for the stock is 22.84x. This Fair Ratio is a proprietary estimate of what the P/E might be given factors such as earnings growth, industry, profit margins, market cap and key risks.

Compared with simple peer or industry comparisons, the Fair Ratio aims to be more tailored because it brings those company specific drivers together rather than relying on broad group averages alone.

The current P/E of 54.27x sits meaningfully above the Fair Ratio of 22.84x. This points to the shares pricing in a higher multiple than this framework suggests.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Hims & Hers Health Narrative

Earlier the article mentioned that there is an even better way to think about valuation, so this is where Narratives come in as a simple way to connect your view of Hims & Hers Health with the numbers behind it.

A Narrative is your story for the company, where you set what you believe are reasonable future revenue, earnings and margin paths and the fair value those assumptions point to, instead of just accepting a single target from a model.

On Simply Wall St, Narratives live inside the Community page, where millions of investors already share views. Each Narrative links three parts together: the business story, a forecast and a fair value that you can compare directly with the current price to help decide whether you see Hims & Hers Health as closer to fairly priced or as offering a margin between price and value.

Narratives also update automatically when new earnings, guidance or news are added to the platform, so the figures you see stay aligned with the latest information.

For Hims & Hers Health, one community Narrative currently applies a fair value of US$173.02 per share based on assumptions about multi dimensional revenue expansion. Another uses US$50.07 per share with more moderate growth and profitability inputs, showing how different investors can look at the same company and reach very different, but clearly explained, conclusions.

For Hims & Hers Health however we will make it really easy for you with previews of two leading Hims & Hers Health Narratives:

Fair value: US$86.09 per share

Implied discount to this fair value: about 64.5%

Revenue growth assumption: 22%

• Frames Hims & Hers Health as a healthcare platform that integrates diagnosis, treatment and prevention rather than just a telehealth or single product business.
• Highlights a balance sheet with no debt, positive free cash flow and a focus on scaling personalised, subscription based care to deepen customer relationships.
• Flags meaningful regulatory, legal and execution risks around GLP 1s, advertising and rapid category expansion, but still sees a large long term opportunity in consumer focused healthcare.

Fair value: US$24.31 per share

Implied premium to this fair value: about 25.7%

Revenue growth assumption: 15.63%

• Sees growth coming from new categories like hormonal health, at home testing and international markets, but expects that to come with regulatory and operational trade offs.
• Points out that heavy spending on technology, marketing and infrastructure, along with reliance on a few high growth segments such as GLP 1 weight loss, could weigh on margins if results fall short.
• Uses analyst assumptions and price targets to suggest the shares are close to fairly priced against forecast earnings, with limited room for disappointment on execution or regulation.

If you want to go beyond these summaries and see how other investors are framing the trade off between growth potential and risk, you can read the full set of community Narratives for Hims & Hers Health alongside the detailed numbers that sit behind them, then compare those views with your own expectations for the business over the next few years.

Do you think there's more to the story for Hims & Hers Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.